# BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

> **NCT06793332** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 39 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)
- Brain Metastases

## Interventions

- **DRUG:** Ivonescimab Combined With TROP2 ADC

## Key facts

- **NCT ID:** NCT06793332
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2026-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793332, "BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06793332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*